July 28, 2026 NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer’s Disease Read More
June 29, 2026 NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS Read More
May 7, 2025 NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch Read More
April 10, 2025 NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC’s Promise as a Disease-Modifying ALS Treatment Read More
December 24, 2024 NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS Read More
December 11, 2024 NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC Read More
July 28, 2026 NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer’s Disease Read More
June 29, 2026 NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS Read More
May 7, 2025 NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch Read More
April 10, 2025 NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC’s Promise as a Disease-Modifying ALS Treatment Read More
December 24, 2024 NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS Read More
December 11, 2024 NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC Read More
December 2, 2024 NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price Read More
